Author

Linnea Aziz Page 2

An infusion center pharmacist in Bellingham, Washington, Linnea Aziz, PharmD, BCPS, BCOP, reviews every chemotherapy regimen before medications are prepared for patients. She worked as a clinical hospital pharmacist before specializing in oncology, with a focus on targeted therapies and adverse side effects. Aziz received a BS in Pharmaceutical Sciences from Concordia University Wisconsin and a PharmD from Albany College of Pharmacy and Health Sciences, maintaining her clinical practice alongside her professional certifications.

What Are EGFR TKI Drugs and How Do They Work?
What Is Dinaciclib and How Does It Work for Cancer?
Lazertinib vs. Osimertinib: Which Is Better for Lung Cancer?
Elacestrant vs Fulvestrant for Breast Cancer Treatment
Adebrelimab: A New Cancer Immunotherapy Treatment
What Is a CART Drug? Peptides vs. T-Cell Therapy
What Is an MCL1 Inhibitor and How Does It Work?
Abraxane vs. Paclitaxel: Key Differences in Treatment
Osimertinib Resistance: Why It Happens and What to Do Next
What Is an IDO1 Inhibitor and How Does It Work?
Ramucirumab’s Mechanism of Action in Cancer Therapy
What Is Cadonilimab? A Bispecific Cancer Immunotherapy
EGFR Inhibitors: Mechanism, Uses, and Side Effects
What Is the Camptothecin Mechanism of Action?
Decitabine and Venetoclax: A Combination Cancer Therapy
How Does Cetuximab’s Dual Mechanism of Action Work?
Dasatinib vs. Imatinib: A Comparison of Cancer Therapy
Capivasertib Mechanism of Action: AKT Inhibition, Tumor Control
BTK Degrader: Mechanisms and Therapeutic Impact
Divarasib for KRAS G12C Tumors: A Promising Breakthrough
CDK 4/6 Inhibitors: Mechanisms, Applications, and Insights
Cisplatin Eligibility: Criteria for Safe and Effective Use